Insmed Incorporated
INSM
Classificação em ações
#1107
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Preço da ação
$95.65
Última sincronização: 2026-10-19
Valor de mercado
$20.89B
Variação (1 dia)
-0.65%
Variação (1 ano)
-43.04%
País
US
Negociar Insmed Incorporated (INSM)
Categoria
Healthcare
Lucros da Insmed Incorporated (INSM)
Lucros em Jun 2026 TTM: $-869.11M
De acordo com os últimos relatórios financeiros da Insmed Incorporated, os ganhos atuais da empresa são de $-869.11M. Em 2023, a empresa teve ganhos de $-747.01M, uma diminuição em relação a aos ganhos de 2022, que foram de $-480.15M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Insmed Incorporated de 2000 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-869.11M | -4.50% |
| 2024 | $-910.07M | 21.83% |
| 2023 | $-747.01M | 55.58% |
| 2022 | $-480.15M | 10.02% |
| 2021 | $-436.41M | 49.10% |
| 2020 | $-292.69M | 15.43% |
| 2019 | $-253.56M | -21.76% |
| 2018 | $-324.08M | 67.98% |
| 2017 | $-192.92M | 9.51% |
| 2016 | $-176.18M | 46.62% |
| 2015 | $-120.15M | 34.13% |
| 2014 | $-89.58M | 56.35% |
| 2013 | $-57.29M | 38.48% |
| 2012 | $-41.37M | -30.66% |
| 2011 | $-59.66M | 838.70% |
| 2010 | $-6.36M | -105.35% |
| 2009 | $118.83M | -858.45% |
| 2008 | $-15.67M | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-36.42M | -2.02% |
| 2001 | $-37.17M | -53.34% |
| 2000 | $-79.66M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | -706.93% |
US
|
|
| $-3.09B | 255.19% |
US
|
|
| $-4.02B | 362.11% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -324.44% |
NL
|
